Boothbay Fund Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Boothbay Fund Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-21,800	Closed	-$1.93M	–	1667
2023 Q3	$1.93M	Buy	21,800 +1,800	+9%	+$160K	0.05%	516
2023 Q2	$1.73M	Buy	20,000 +11,400	+133%	+$1.07M	0.04%	616
2023 Q1	$836K	Buy	8,600 +6,100	+244%	+$632K	0.02%	1074
2022 Q4	$259K	Sell	2,500 -69,000	-97%	-$6.48M	0.01%	1468
2022 Q3	$6.06M	Buy	+71,500	New	+$6.37M	0.15%	144
2022 Q2	–	Sell	-33,300	Closed	-$2.57M	–	2266
2022 Q1	$2.57M	Buy	33,300 +13,100	+65%	+$1.1M	0.06%	470
2021 Q4	$1.78M	Buy	+20,200	New	+$1.67M	0.04%	515
2020 Q2	–	Sell	-68	Closed	-$574K	–	975
2020 Q1	$574K	Buy	+68	New	+$5.86K	0.05%	431
2019 Q3	–	Sell	-40	Closed	-$343K	–	771
2019 Q2	$343K	Sell	40 -81	-67%	-$6.93K	0.03%	508
2019 Q1	$1.07M	Buy	+121	New	+$11.2K	0.1%	216
2016 Q2	–	Sell	-4,800	Closed	-$396K	–	534
2016 Q1	$396K	Buy	+4,800	New	+$391K	0.1%	310

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Boothbay Fund Management's BMRN Position: Q2 2026 in Review

Boothbay Fund Management increased its BioMarin Pharmaceuticals (BMRN) stake by 89% in Q2 2026, buying an estimated $1.67M and bringing the position to 64,733 shares worth $3.7M. The position accounts for 0.05% of the portfolio, ranked #442.

Boothbay Fund Management first reported a position in BMRN in Q1 2017 and has held it in 13 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Boothbay Fund Management held 64,733 shares of BioMarin Pharmaceuticals worth $3.7M as of Q2 2026.
Boothbay Fund Management bought 30,527 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.67M.
BioMarin Pharmaceuticals made up 0.05% of Boothbay Fund Management's portfolio in Q2 2026, its #442 holding.
Boothbay Fund Management first reported a position in BioMarin Pharmaceuticals in Q1 2017 and has held it in 13 quarters since.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.